Literature DB >> 17203190

Clinical factors in prediction of prognosis after anterior resection with total mesorectal excision for carcinoma of the rectum.

Bartlomiej Szynglarewicz1, Rafal Matkowski, Jozef Forgacz, Marek Pudelko, Zbigniew Smorag, Jacek Dryl, Jan Kornafel.   

Abstract

The aim of the study was to estimate the long-term results and the prognostic value of clinical and pathological factors following R0 anterior resection with total mesorectal excision (TME). Ninety-eight consecutive patients with histologically confirmed rectal cancer were studied prospectively with five-year follow-up. Survival was calculated using the Kaplan-Meier method and differences between curves were tested by the log-rank test. Multivariate analysis was performed using the Cox regression model. Recurrence-free survival (RFS) was 63.6%. Mean time of recurrence was 13.8 months (range 3-38). Local recurrence rate was 7.8% with the mean time of 12.7 months (range 3-25). In univariate analysis Dukes' stage (RFS for stage: A=93.2%; B=53.8%; C=26.3%) and preoperative CEA serum level (s-CEA) (for s-CEA<or=5 ng/ml RFS=93.8%; for s-CEA>5 ng/ml RFS=5.9%) significantly influenced survival (P<0.005 and P<0.00001). These parameters were also found to be independent prognostic factors in multivariate analysis (P<0.05 and P<0.00001). Survival was worse in older female patients with low-localised poorly differentiated tumors; however, those variables had not significant impact on prognosis. Neither symptom duration nor mucinous histology was significantly related to survival. Using TME technique a low local recurrence rate resulting in improved survival can be achieved. Apart from clinicopathological staging, elevated s-CEA can identify patients with poor prognosis. In addition to TME adjuvant therapy for this high-risk group should be considered.

Entities:  

Mesh:

Year:  2007        PMID: 17203190

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Preoperative carcinoembryonic antigen and prognosis of colorectal cancer. An independent prognostic factor still reliable.

Authors:  Giovanni Li Destri; Antonio Salvatore Rubino; Rosalia Latino; Fabio Giannone; Raffaele Lanteri; Beniamino Scilletta; Antonio Di Cataldo
Journal:  Int Surg       Date:  2015-04

2.  Study of therapeutic results, lymph node ratio, short-term and long-term complications of lateral lymph node dissection in rectal cancer patients.

Authors:  Habibollah Mahmoodzadeh; Ramesh Omranipour; Anahita Borjian; Mohammad Amin Borjian
Journal:  Turk J Surg       Date:  2020-06-08

3.  Prognostic value of lateral lymph node metastasis for advanced low rectal cancer.

Authors:  Ze-Yu Wu; Jin Wan; Jing-Hua Li; Gang Zhao; Yuan Yao; Jia-Lin Du; Quan-Fang Liu; Lin Peng; Zhi-Du Wang; Zhi-Ming Huang; Hua-Huan Lin
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

4.  Association between histological type of tumour growth and patient survival in t2-t3 lymph node-negative rectal cancer treated with sphincter-preserving total mesorectal excision.

Authors:  Bartlomiej Szynglarewicz; Rafal Matkowski; Agnieszka Halon; Aleksandra Lacko; Marcin Stepien; Jozef Forgacz; Marek Pudelko; Jan Kornafel
Journal:  Pathol Oncol Res       Date:  2009-09-15       Impact factor: 3.201

5.  Sphincter-preserving R0 total mesorectal excision with resection of internal genitalia combined with pre- or postoperative chemoradiation for T4 rectal cancer in females.

Authors:  Bartlomiej Szynglarewicz; Rafal Matkowski; Piotr Kasprzak; Daniel Sydor; Jozef Forgacz; Marek Pudelko; Jan Kornafel
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

6.  Value of ¹⁸F-FDG PET-CT in surveillance of postoperative colorectal cancer patients with various carcinoembryonic antigen concentrations.

Authors:  Yan Zhang; Bin Feng; Guo-Li Zhang; Man Hu; Zheng Fu; Fen Zhao; Xiao-Li Zhang; Li Kong; Jin-Ming Yu
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.